Cargando…
A Retrospective Review of Center for Biologics Evaluation and Research Advisory Committee Meetings in the Context of the FDA’s Benefit-Risk Framework
The US FDA Center for Biologics Evaluation and Research (CBER) is responsible for the regulation of biologically derived products. FDA has established Advisory Committees (AC) as vehicles to seek external expert advice on scientific and technical matters related to the development and evaluation of...
Autores principales: | Mutanga, Jane Namangolwa, Nukala, Ujwani, Rodriguez Messan, Marisabel, Yogurtcu, Osman N., McCormick, Quinn, Sauna, Zuben E., Whitaker, Barbee I., Forshee, Richard A., Yang, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911185/ https://www.ncbi.nlm.nih.gov/pubmed/36759415 http://dx.doi.org/10.1208/s12248-023-00789-3 |
Ejemplares similares
-
Mathematical model of a personalized neoantigen cancer vaccine and the human immune system
por: Rodriguez Messan, Marisabel, et al.
Publicado: (2021) -
The effects of lobbying on the FDA’s recall classification
por: Zhou, Yifan
Publicado: (2023) -
A Quantitative Evaluation of COVID-19 Epidemiological Models
por: Yogurtcu, Osman N., et al.
Publicado: (2021) -
Physician Perceptions of the FDA’s Breakthrough Therapy Designation: An Update
por: Paquin, Ryan S, et al.
Publicado: (2022) -
LAWS, REGULATIONS, AND POLICY: Genetically Engineered Salmon on the FDA’s Table
por: Taylor, David A.
Publicado: (2010)